title: Optic atrophy and macular degeneration as initial presentations of subacute sclerosing panencephalitis.
abstract: OBJECTIVE
  To report a case of subacute sclerosing panencephalitis in which the initial clinical presentations were optic atrophy and macular degeneration.
  
  
  METHODS
  Observational case report.
  
  
  METHODS
  A 9-year-old boy with visual loss attributable to optic atrophy and macular degeneration had a diagnostic examination.
  
  
  RESULTS
  The visual acuity levels of both eyes were light perception at presentation. Fundus examination revealed bilateral optic atrophy and macular degenerative changes including retinal pigment epithelial atrophy, macular scarring, and epiretinal membrane formation. The antimeasles IgG titers were high both in serum and cerebrospinal fluid samples. Neurologic symptoms of myoclonus, ataxia, motor, and mental disabilities occurred 4 months after the onset of first visual disturbances and 2 weeks after the patient applied to our clinic.
  
  
  CONCLUSIONS
  Children with optic atrophy and macular degenerative lesions should be examined for sclerosing panencephalitis, even if the classical neurologic symptoms of this disease are not present.
authors.affiliation: Department of Ophthalmology, Ankara Social Insurance Hospital, Turkey.
authors.forename: Nilufer
authors.initials: N
authors.lastname: Berker
authors.forename: Cosar
authors.initials: C
authors.lastname: Batman
authors.forename: Alev
authors.initials: A
authors.lastname: Guven
authors.forename: Solmaz
authors.initials: S
authors.lastname: Ozalp
authors.forename: Ozlem
authors.initials: O
authors.lastname: Aslan
authors.forename: Orhan
authors.initials: O
authors.lastname: Zilelioglu
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000276:immunology; D002648:Child; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007542:Inosine Pranobex / Q000627:therapeutic use; D008268:Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008459:Measles virus / Q000276:immunology; D009896:Optic Atrophy / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D013344:Subacute Sclerosing Panencephalitis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D014792:Visual Acuity
chemical_list: D018712:Analgesics, Non-Narcotic; D000914:Antibodies, Viral; D000998:Antiviral Agents; D007074:Immunoglobulin G; D002220:Carbamazepine; D007542:Inosine Pranobex